公开(公告)号：US20080124280A1

公开(公告)日：2008-05-29

申请号：US11663047

申请日：2005-09-15

Applicant: Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

Inventor： Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

IPC: A61K9/127 ,  A61K31/195 ,  A61K31/7076 ,  A61K31/727 ,  A61K31/4365 ,  A61K39/395 ,  A61K49/00 ,  A61P25/28 ,  A61P25/00 ,  A61K49/10 ,  A61K9/14 ,  A61K9/00 ,  A61K31/60 ,  A61K38/04 ,  A61K31/192

CPC classification number: A61K31/192 ,  A61K31/195 ,  A61K31/4365 ,  A61K31/60 ,  A61K31/7076 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/1866 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K49/0008 ,  A61K49/085 ,  A61K49/10 ,  A61K49/12 ,  A61K51/0402 ,  A61K51/0497 ,  A61K51/065 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/43 ,  A61L2300/606 ,  A61K2300/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素或其拮抗剂的聚合形式，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US07332161B2

公开(公告)日：2008-02-19

申请号：US11343003

申请日：2006-01-30

Applicant: Robert W. Colman ,  Shaker A. Mousa

Inventor： Robert W. Colman ,  Shaker A. Mousa

IPC: A61K39/395

CPC classification number: C07K16/36 ,  A61K2039/505 ,  C07K2317/73 ,  C07K2317/76

Abstract: Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.

Abstract translation: 针对高分子量激肽原结构域5（特别是位于由轻链氨基酸Gly（440）至Lys（502）形成的区域中的决定簇）的抗原决定簇的抗体抑制血管发生。

公开(公告)号：US06908907B2

公开(公告)日：2005-06-21

申请号：US10125882

申请日：2002-04-22

Applicant: Mawaheb M. EL-Naggar ,  Shaker A. Mousa

Inventor： Mawaheb M. EL-Naggar ,  Shaker A. Mousa

IPC: A61K38/17 ,  A61K45/06 ,  A61K31/727 ,  A61K3/422

CPC classification number: A61K45/06 ,  A61K9/0019 ,  A61K38/1777 ,  A61K47/36 ,  A61K2300/00

Abstract: This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might include the following: UFH or low molecular weight heparin, (LMWH), ultra LMWH, pentasaccharide or direct anti-Xa or direct anti-IX/IXa, direct anti-IIa (thrombin) or tissue factor pathway inhibitor (TFPI) by any means that produces contact of the agents with their site of action wherein at least one of the components of each of these combinations is given in reduced amount. This combined formulation could be used as a stand-alone regimen or in conjunction with other therapies (chemotherapy, radiotherapy, angiogenesis inhibitors, . . . ), and pre- & post-tumor surgery in the prevention and treatment of cancer associated metastasis, angiogenesis, tumor growth, and thrombosis.

Abstract translation: 本发明通过组合施用可能包括以下的短效应或长效GPIIb / IIIa拮抗剂（A）和抗凝血剂（B）来预防和治疗肿瘤生长，转移和癌症介导的血栓形成： UFH或低分子量肝素（LMWH），超LMWH，五糖或直接抗Xa或直接抗IX / IXa，直接抗IIa（凝血酶）或组织因子途径抑制剂（TFPI）通过任何方式产生接触 具有其作用位点的试剂，其中以减少的量给予这些组合中的每一种的至少一种组分。 该组合制剂可用作独立方案或与其他疗法（化学疗法，放射治疗，血管生成抑制剂，...）和肿瘤前和手术后预防和治疗癌症相关转移，血管生成 ，肿瘤生长和血栓形成。